Immix Biopharma (IMMX) Q2 2026 earnings summary

Executive summary

• Lead CAR-T therapy NXC-201 completed Phase 1b/2 trial enrollment for AL Amyloidosis; FDA granted Breakthrough Therapy, RMAT, and Orphan Drug designations in 2026.

• Interim Phase 2 data showed a 95% complete response rate and favorable safety profile; plans for Phase 3 trial initiation.

• Company operates as a single segment focused on cell therapy development, with ongoing expansion of pipeline and clinical programs.

Financial highlights

• Cash, cash equivalents, and short-term investments totaled $232.1 million as of June 30, 2026; working capital was $224.5 million.

• Net loss was $11.6 million for Q2 2026 (vs. $6.6 million Q2 2025) and $21.6 million for the first half of 2026 (vs. $11.2 million first half 2025).

• Operating expenses rose to $12.5 million in Q2 2026, driven by increased R&D and G&A costs.

• Interest income increased to $913,663 in Q2 2026 due to higher cash balances.

Outlook and guidance

• Cash runway expected to fund operations for at least 12 months from the filing date; additional capital will be needed for long-term plans.

• Expenses projected to rise as clinical and development activities expand, including potential commercialization costs.